Search is Powered by Google
Lymphoma / Leukemia News

Regulating Hematopoietic Stem Cell Homeostasis And Leukemogenesis

Main Category: Lymphoma / Leukemia
Also Included In: Stem Cell Research;  Biology / Biochemistry
Article Date: 15 Apr 2008 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

In the April 15th issue of G&D, Dr. Richard Flavell (Yale University) and colleagues identify the c-Cbl protein as a critical repressor of hematopoietic stem cell (HSC) self-renewal. In addition to establishing a key role for protein ubiquitylation in HSC development, this finding posits c-Cbl as a potential target in research into stem cell engineering as well as cell-based leukemia treatments.

Dr. Flavell describes the work as elucidating "a novel dimension in our understanding the self-renewal of Hematopoietic stem cells."

Like all stem cell populations, HSC reply upon asymmetric cell division to generate two different daughter cells: one future stem cell, and another cell that will further differentiate into a more specialized cell type. Thus, a balance is struck between the production of new cell types and the renewal of the stem cell pool. However, imbalances between HSC self-renewal and differentiation can lead to hematologic malignancies like leukemia.

Dr. Flavell's group discovered that the E3 ubiquitin ligase, c-Cbl, suppresses HSC self-renewal. The researchers generated transgenic mice deficient in c-Cbl, and demonstrated that these c-Cbl-mutant mice display an increased number of HSCs.

Lead author, Dr. Chozhavendan Rathinam, is confident that "our findings may facilitate the expansion and manipulation of hematopoietic stem cells for tissue engineering and stem cell based therapies."

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Source: Heather Cosel-Pieper
Cold Spring Harbor Laboratory




Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Breast Cancer Cardiovascular GI Prostate Cancer Psychiatry Respiratory Learning Resources Migraine Urology
Asthma Bipolar Blood Pressure Breast Cancer (Patient) Heartburn

Sign up to receive newsletters / news alerts
MedReader RSS Reader


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Monitoring CML image Monitoring CML

A wide range of laboratory tests is used to monitor a patient's response to therapy for chronic myeloid leukemia. Listen to experts explain the tests and their range of sensitivity...

View more videos...

Add Your Advertisement Here